startup
Cambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease work
Source:
eu-startups.com 1 min read
Share
You are reading a summary. The full content is hosted on eu-startups.com.
TRIMTECH Therapeutics, a Cambridge-based BioTech company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, has raised an additional €12 million ($14 million) in Seed funding to progress its proprietary platforms and differentiated portfolio. The financing was led by Johnson & Johnson’s corporate venture capital organisation, Johnson & Johnson […] The post Cambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease work appeared first on EU-Startups.
Read the full article on the original website
External link to eu-startups.com
Related Articles
startup
Sources: Uber halts plans to launch food delivery in five of the seven European countries it had targeted for expansion as it pursues a Delivery Hero takeover (Kieran Smith/Financial Times)
1 min read •
startup
India issues a notice to Telegram, asking it to curb the spread of pirated films and other copyrighted content, and seeks an action-taken report within 15 days (Sejal Sharma/Hindustan Times)
1 min read •
startup
Trump's God, guns and anticommunist Fourth of July
2 min read •